NIKKEI 225
39,341.54 -325.53 (-0.82%) HANG SENG
17,716.47 -373.46 (-2.06%) CRUDE OIL
81.88 +0.14 (+0.17%) GOLD FUTURES
2,338.20 +1.60 (+0.07%) DOW
39,164.06 +36.26 (+0.09%) Bitcoin GBP
48,725.75 +638.95 (+1.33%)
BioNTech SE (22UA.F)
| Previous close | 78.05 |
| Open | 76.90 |
| Bid | 75.05 x N/A |
| Ask | 76.05 x N/A |
| Day's range | 75.00 - 77.55 |
| 52-week range | 75.00 - 116.00 |
| Volume | |
| Avg. volume | 1,151 |
| Market cap | 18.074B |
| Beta (5Y monthly) | 0.27 |
| PE ratio (TTM) | 159.57 |
| EPS (TTM) | 0.47 |
| Earnings date | 06 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 02 Jun 2022 |
| 1y target est | 334.89 |
Globe NewswirePfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the European Union
The updated COVID-19 vaccine is tailored to the Omicron JN.1 lineage of SARS-CoV-2 and is recommended for individuals 6 months of age and olderRecommendation is based on pre-clinical and epidemiological data showing that the JN.1-adapted monovalent COVID-19 vaccine generates an improved immune response against multiple JN.1 sublineagesDoses will be ready to ship to applicable EU member states immediately upon authorization by the European Commission NEW YORK and MAINZ, Germany, June 27, 2024 — P
- Globe Newswire
BioNTech and DualityBio Receive FDA Fast Track Designation for Antibody-Drug Conjugate Candidate BNT324/DB-1311 in Prostate Cancer
Designation is based on pre-clinical data and data from an ongoing Phase 1/2 trial for BNT324/DB-1311, with antitumor activity and a manageable safety profile demonstrated by preliminary Phase 1/2 clinical data from patients with advanced or metastatic solid tumors1,2With the Fast Track designation, the development of BNT324/DB-1311 can benefit from more frequent engagement with the U.S. Food and Drug Administration (“FDA”) to support development and expedite regulatory reviewProstate cancer is
BenzingaCovid-19 Pharma Stars Continue Their Quest To Set New Standards In Cancer Treatment
AstraZeneca PLC (NASDAQ: AZN) kicked off the week by receiving approval from the U.S. Food and Drug Administration for its blockbuster cancer drug Imfinzi combined with chemotherapy being used as a treatment forpatients suffering from specific type of endometrial cancer. Its pharma peer, BioNTech SE (NASDAQ: BNTX) wasn’t as lucky as also on Monday, the FDA put its experimental cancer drug study on partial clinical hold. Combining Immunotherapy And Chemotherapy Is Emerging As A New Standard In Ca
